Menu Search
Equities

Ocugen Inc

2H51:DUS

Ocugen Inc

Actions
  • Price (EUR)0.8435
  • Today's Change-0.022 / -2.54%
  • Shares traded2.26k
  • 1 Year change+147.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

  • Revenue in USD (TTM)9.33m
  • Net income in USD-49.67m
  • Incorporated2006
  • Employees65.00
  • Location
    Ocugen Inc11 GREAT VALLEY PARKWAYMALVERN 19355United StatesUSA
  • Phone+1 (484) 328-4701
  • Fax+1 (302) 655-5049
  • Websitehttps://ocugen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.